Pathological mechanisms and novel drug targets in fibrotic interstitial lung disease
Abstract Background Interstitial lung diseases (ILDs) are a diverse group of conditions characterized by inflammation and fibrosis in the lung. In some patients with ILD, a progressive fibrotic phenotype develops, which is associated with an irreversible decline in lung function and a poor prognosis...
Saved in:
Main Authors: | Yasuhiko Nishioka (Author), Jun Araya (Author), Yoshiya Tanaka (Author), Atsushi Kumanogoh (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2024-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Enhancing Outcomes in Chronic Fibrotic Interstitial Lung Disease Through Aggressive Management of Nintedanib-Induced Adverse Drug Reactions: A Retrospective Analysis
by: Yu-Wen Chang, et al.
Published: (2024) -
Novel understandings of host cell mechanisms involved in chronic lung infection: Pseudomonas aeruginosa in the cystic fibrotic lung
by: Peter Anto Johnson
Published: (2019) -
Case report: Fibrotic interstitial lung disease as the initial manifestation of hereditary pulmonary alveolar proteinosis caused by CSF2RB mutation
by: Qiuhong Li, et al.
Published: (2024) -
Drugs associated with drug-induced interstitial lung diseases
by: O. D. Ostroumova, et al.
Published: (2021) -
Interstitial Lung Diseases
Published: (2019)